Brind.

PTC Therapeutics seeks FDA approval for Sephience™, backed by positive Phase 2 results in Huntington's Disease, and plans a global launch in Europe.

3 reports, 2 independent Updated Aug 8
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
4
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

PTC Therapeutics seeks FDA approval for Sephience™, backed by positive Phase 2 results in Huntington's Disease, and plans a global launch in Europe.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA approved Sephience for PKU treatment, with ongoing review applications in Japan and Brazil.Sub-event
  2. PTC Therapeutics is seeking FDA approval for Sephience™, which showed positive Phase 2 results for Huntington's Disease.1 source
  3. FDA approved PTC's Sephience for PKU treatment.1 source
  4. Sephience achieved FDA approval as an oral therapy.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • PR NewswirePTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results – European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch unde
  • ZacksPTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? PTC Therapeutics (PTCT) shares ended the last trading session 11.2% higher at $49.29. The jump came on an impressive volu
  • PR NewswireOrsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE™ (sepiapterin) SEPHIENCE is an FDA-approved oral therapy for the treatment of phenylketonuria (PKU) ELK GROVE VILLAGE, Il